ES2139673T3 - Utilizacion de norastemizol para el tratamiento de rinitis alergica. - Google Patents

Utilizacion de norastemizol para el tratamiento de rinitis alergica.

Info

Publication number
ES2139673T3
ES2139673T3 ES93921359T ES93921359T ES2139673T3 ES 2139673 T3 ES2139673 T3 ES 2139673T3 ES 93921359 T ES93921359 T ES 93921359T ES 93921359 T ES93921359 T ES 93921359T ES 2139673 T3 ES2139673 T3 ES 2139673T3
Authority
ES
Spain
Prior art keywords
treatment
allergic rhinitis
norastemizol
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921359T
Other languages
English (en)
Inventor
Raymond L Woosley
A K Gunnar Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ES2139673T3 publication Critical patent/ES2139673T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO DE FORMULA (I), O UNA SAL DEL MISMO FARMACEUTICAMENTE ACEPTABLE, PARA USO EN UN TRATAMIENTO ANTI-HISTAMINICO, QUE NO ORIGINA ARRITMIA CARDIACA SIGNIFICATIVA ALGUNA, COMPRENDIENDO UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DEL COMPUESTO DE FORMULA (I) A UN PACIENTE HUMANO.
ES93921359T 1992-09-03 1993-09-03 Utilizacion de norastemizol para el tratamiento de rinitis alergica. Expired - Lifetime ES2139673T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94005492A 1992-09-03 1992-09-03

Publications (1)

Publication Number Publication Date
ES2139673T3 true ES2139673T3 (es) 2000-02-16

Family

ID=25474141

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99200247T Expired - Lifetime ES2210957T3 (es) 1992-09-03 1993-09-03 Composiciones farmaceuticas que contienen norastemizol.
ES93921359T Expired - Lifetime ES2139673T3 (es) 1992-09-03 1993-09-03 Utilizacion de norastemizol para el tratamiento de rinitis alergica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99200247T Expired - Lifetime ES2210957T3 (es) 1992-09-03 1993-09-03 Composiciones farmaceuticas que contienen norastemizol.

Country Status (13)

Country Link
US (5) US6130233A (es)
EP (3) EP0920865B1 (es)
JP (3) JPH08501083A (es)
AT (2) ATE187642T1 (es)
AU (1) AU687746B2 (es)
CA (1) CA2143610C (es)
DE (3) DE4394931T1 (es)
DK (2) DK0920865T3 (es)
ES (2) ES2210957T3 (es)
GB (1) GB2285219B (es)
GR (1) GR3032541T3 (es)
PT (2) PT920865E (es)
WO (1) WO1994007495A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
WO1998042379A2 (en) * 1997-03-26 1998-10-01 Sepracor Inc. Chemically and thermally stable norastemizole formulations
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
EP2106784B1 (en) * 2008-04-03 2015-04-22 Rohm and Haas Company Hair styling composition
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
EP0144101B1 (en) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines
DE3781173T2 (de) * 1986-02-03 1992-12-17 Janssen Pharmaceutica Nv N-heterozyklische-4-piperidinamine enthaltende anti-histaminische zusammensetzungen.
US4835161A (en) * 1986-02-03 1989-05-30 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
WO1999032125A1 (en) 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

Also Published As

Publication number Publication date
US6130233A (en) 2000-10-10
GR3032541T3 (en) 2000-05-31
GB2285219B (en) 1996-09-11
PT920865E (pt) 2004-06-30
AU687746B2 (en) 1998-03-05
EP0658110A1 (en) 1995-06-21
US6187794B1 (en) 2001-02-13
CA2143610A1 (en) 1994-04-14
EP0920865A1 (en) 1999-06-09
PT658110E (pt) 2000-06-30
AU4848093A (en) 1994-04-26
ES2210957T3 (es) 2004-07-01
DE4394931T1 (de) 1995-07-20
EP0658110B1 (en) 1999-12-15
GB9504329D0 (en) 1995-04-26
US6124320A (en) 2000-09-26
WO1994007495A1 (en) 1994-04-14
DK0920865T3 (da) 2004-04-19
EP1262183A1 (en) 2002-12-04
DE69327328D1 (de) 2000-01-20
CA2143610C (en) 2004-08-24
ATE257704T1 (de) 2004-01-15
DK0658110T3 (da) 2000-04-17
DE69333387D1 (de) 2004-02-19
EP0920865B1 (en) 2004-01-14
JPH08501083A (ja) 1996-02-06
DE69333387T2 (de) 2004-12-09
US6187795B1 (en) 2001-02-13
JP2002255817A (ja) 2002-09-11
US6268382B1 (en) 2001-07-31
DE69327328T2 (de) 2000-06-21
JP2002308772A (ja) 2002-10-23
GB2285219A (en) 1995-07-05
ATE187642T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
SE9901573D0 (sv) New compounds
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
SE9901572D0 (sv) New compounds
KR890001555A (ko) 요산 배설용 조성물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658110

Country of ref document: ES